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RCAS1 and B7H4 
antigens immunoreactivity in 
squamous cell carcinoma of palatine 
tonsils and cancer microenvironment
ABStRACt
B7-H4 protein has been demonstrated to be over-expressed by various types of cancer cells. The level 
of expression of B7-H4 in these cancers is related to the type of cancer, its stage, and the number of 
Treg cells, and correlates with patient survival and might be a new therapeutic target. The major role of 
RCAS1 expression is to inhibit activated immune cells, such as T and B lymphocytes and NK cells, and 
to induce their apoptosis. It has also been postulated that RCAS1 is involved in the remodelling of the 
tumour microenvironment. 
The aim of the present study has been to evaluate RCAS1- and B7-H4-antigen immunoreactivity in squa-
mous cell carcinoma of the palatine tonsils and in the cancer microenvironment. For our study, we recruited 
30 patients with primary squamous cell carcinoma originating from the palatine tonsils. 
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Results 
B7-H4 antigen was over-expressed in cancerous 
tonsillar tissue and was significantly higher in those pa-
tients with the presence of lymph node metastases. The 
immunoreactivity of B7-H4 in the cancerous tumour 
microenvironment was represented by macrophages 
and cancer-associated fibroblasts and was statistically 
significantly associated with the presence of lymph 
node metastases. RCAS1 antigen over-expression was 
identified in palatine tonsil squamous cell carcinoma 
cells and associated with the presence of lymph node 
metastases. 
Conclusions 
Our study seems to indicate that both RCAS1- and 
B7-H4- immunopositive macrophages, together with 
B7H4 immunopositive cancer-associated fibroblasts, 
may play an important role in creating the suppressive 
profile of the tumour microenvironment of patients with 
tonsillar cancer.
Introduction
For a long time, it has been recognized by various 
pathologists that the tumour-associated inflammatory 
response promotes tumorigenesis as well as the pro-
gression of cancer. The presence of an aggressive 
tumour phenotype is related to the local infiltration of 
cancer cells and the potential to develop lymph node 
metastases. This phenotype is also associated with 
the intensity of creating the suppressive profile of the 
tumour microenvironment or the tumour cells that create 
the cancer microenvironment. This microenvironment 
determines the growth and progression of a tumour and 
initiates the ability to metastasize. The tumour stroma 
is infiltrated by immune system cells which represent 
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the phenotype that supports tumour growth, such as 
tumour-associated macrophages (TAMs). It has been 
demonstrated that the suppressive phenotype of macro-
phages is linked with the expression of such membrane 
proteins as RCAS1 and HLA-G [1 –4]. The local invasion 
of cancer is associated with the process of cancer 
stroma remodelling and the epithelial to mesenchymal 
transition. During this process, the stromal fibroblasts 
change their phenotype into cancer-associated fi-
broblasts (CAFs). This change is related to different 
protein expression profiles. Recently, both RCAS1 and 
B7-H4 antigens have been observed to be expressed 
by CAFs and been associated with the clinical outcome 
of the disease [3, 5–7]. 
The B7-H4 molecule belongs to the B7 molecule 
family, which includes CD80 and CD86 along with 
the receptors CD28 and cytotoxic T-lymphocyte an-
tigen (CTLA-4). Its major role is to provide positive 
and/or negative co-signalling at the initiation stage of 
T-cell responses, in conjunction with a T-cell receptor 
(TCR)-mediated antigenic signal. B7-H4 mRNA is ex-
pressed in APCs, including brain, thymus, heart, lung, 
liver, stomach, intestinal tract, pancreas, prostate, 
ovary, placenta, urethra, skin, muscle, and bone cells 
[8]. Tumour-associated CD4+CD25+forkhead box 
p3 (Foxp3)+ Treg cells can trigger APCs, including 
macrophages, to produce both IL-6 and IL-10 (38). 
These cytokines stimulate macrophage expression of 
B7-H4, whereas GM-CSF and IL-4 inhibit it [7]. Interest-
ingly, since IL-4, IL-6, IL-10, and GM-CSF have not been 
found to regulate B7-H4 expression on tumour cells, the 
B7-H4 expression on these cells may be functionally 
distinct from that on APCs and may be differentially 
regulated. In accord with this, both Treg cells and 
macrophage B7-H4, but not tumour B7-H4, have been 
negatively associated with patient outcome. B7-H4+ 
tumour macrophages may be a novel suppressor cell 
population in ovarian cancer that can be therapeutically 
targeted [8 –12].
In recent studies, B7-H4 protein has been demon-
strated to be over-expressed by various types of cancer 
cells. The level of expression of B7-H4 in ovarian cancer, 
for example, is related to the type of cancer, its stage, 
and the number of Treg cells, and correlates with patient 
survival. In oral squamous cell carcinoma, B7-H4 was 
highly expressed, and the B7-H4 expression level was 
associated with the clinicopathological parameters of 
the patient’s cancer, such as the pathological grade and 
lymph node status. It was observed that patients with 
high B7-H4 expression had poorer overall survival com-
pared with those patients with low B7-H4 expression. It 
was also suggested that B7-H4 may be a potential target 
in the treatment of oral squamous cell carcinoma [12].
The major role of RCAS1 expression is to inhibit 
activated immune cells, such as T and B lymphocytes 
and NK cells, and to induce their apoptosis. RCAS1 is 
therefore responsible for tumour escape from the host 
immunological surveillance and the creation of immune 
tolerance for tumour cells [13–16]. The RCAS1 expres-
sion has been found in various malignant neoplasms 
and is related to the grade of the tumour, the stage of 
cancer, and the presence of lymph node metastases, 
as well as to a poorer prognosis. It has also been pos-
tulated that RCAS1 is involved in the remodelling of the 
tumour microenvironment in cases of uterine cervical 
cancer [17–20].
The aim of the present study has been to evaluate 
RCAS1- and B7-H4-antigen immunoreactivity in squa-
mous cell carcinoma of the palatine tonsils and in the 
cancer microenvironment (including stromal fibroblasts 
and the macrophages infiltrating the tumour) and to 
analyze its relation to both clinical and pathological pa-
rameters.
Materials and methods
The group of patients
For our study, we recruited patients with primary 
squamous cell carcinoma originating from the pala-
tine tonsils and selected 30 of them. In each of these 
patients, tissue samples were taken from both the 
carcinoma and the tumour microenvironment and 
then analyzed. The microenvironment, or stroma of 
the tumour, is defined as the surrounding 1cm2 of 
tissue that is macroscopically and histologically free of 
cancer infiltration.
For all patients, radical surgery of the tumour was 
performed along with lymphadenectomy. The patient’s 
consent was obtained in each case. Additionally, 
approval for the research program was granted from 
the Ethical Committee of the Jagiellonian University in 
Krakow: KBET/90/B/2005.
All the tissue samples were histopathologically 
verified. Pathological analysis, using the classical he-
matoxylin and eosin staining techniques after fixation 
in a formalin of the surgically removed material, was 
performed in the Pathology Department of the Jagiel-
lonian University by two experienced pathologists (R.T. 
and A.L.) working independently. The tissue material 
was then fixed in the solution of 10% formalin, rinsed, 
dehydrated, and transferred through a progressively 
increasing concentration of ethanol (from 50% to 
absolute alcohol); it was then passed through xylens 
I, II, and III as well as molten paraffin wax. Lastly, the 
tissue blocks were sectioned and placed onto 3-4 mm 
slides. The process was mainly automated, but both 
the paraffin embedding and the sectioning of the 
tissue samples into 3–4 mm slides were performed 
manually. Table 1 presents the characteristics of the 
patient group.
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Reference group
As a reference group, we chose to collect palatine 
tonsils that had been removed from patients due to 
recurrent tonsillitis. In these tissue samples, we evalu-
ated the epithelium lining of the tonsils rather than the 
lymphoid tissue. The characteristics of the reference 
group are presented in Table 2. 
Immunohistochemical analysis
In the present study, we aimed to analyze the 
immunoreactivity levels of various antigens in squa-
mous cell carcinoma of the palatine tonsils and their 
stroma. We were also interested in the distribution of 
the antigen immunoreactivity throughout the tissue of 
a whole tumour, including the stroma. For this reason, 
Table 1. The characteristics of the patient group
Squamous cell carcinoma of the palatine tonsil
The number of patients
M*
W*
30
24
6
Age average
M*
W *
46–70 55.7
46–70 57.3
47–62 55.3
Stage
I
II
III
IV
1
9
16
4
The presence of lymph node metastases
N0
N+
24
6
Tumour size
T1
T2
T3
T4
5
16
7
2
Tumour grading
G1
G2
G3
2
18
10
*Abbreviations: M — men, W — women
Table 2. The characteristics of the reference group
Palatine tonsils 
The number of patients
M*
W*
20
10
9
Age range average
M*
W*
17–56 31.3
21–54 32.5
17–56 26.8
*Abbreviations: M — men, W — women
we chose the immunohistochemistry method for the 
present study. This is the only method that shows the 
actual architecture of the dialogue between a tumour 
and its stroma.
Three to four tissue samples were taken from each 
tumour, depending on the tumour size (if, for instance, 
the tumour was 1cm in diameter, then it was subject to 
further analysis). Each tissue sample was embedded 
in paraffin and formed into a tissue block which was 
then cut into tissue slides. All the tissue slides were 
further histopathologically verified and for the additional 
analysis, the most representative slides were selected 
to undergo immunohistochemistry (for the analysis of 
both a tumour and the stromal samples and in order to 
assess the tumour-stroma interaction).
Immunohistochemical analysis was performed in the 
Pathology Department of the Jagiellonian University. 
Five-micrometre slides from each case were deparaf-
finized, rehydrated, and rinsed in distilled water. Endog-
enous peroxidase activity was blocked by 8 minutes of 
incubation in 3% H2O2 at room temperature. The slides 
were then rinsed and immersed in a boiling citrate buffer 
(pH 6.0) in a microwave oven with three changes of 
buffer for 5 minutes each. In each case, immunohisto-
chemistry was performed applying the Envision method 
using DakoAutostainer. The samples were stained 
automatically. The immunohistochemical staining was 
based on antigen-antibody reaction. Microscopy was 
performed using an Axio Zeiss microscope, and the 
tissue slides were then evaluated under both 20x and 
40x magnification.
Four-micrometer sections from each case, mounted 
on organosilane-pre-treated slides, were stained to 
visualize the expression of both B7-H4 and RCAS1 in 
the various components: cancer cells, stromal cells 
(fibroblasts), and the cells of the inflammatory in-
filtrate reactive to cancer, including macrophages 
(macrophages are characterized by vesicular nuclei 
and distinct, relatively abundant cytoplasm). Previous 
immunostains with lineage-specific antigen CD68 for 
visualization of these cells (CD68, clone PG-M1;DAKO 
Denmark A/S, dilution 1:50, incubation for 30 minutes, 
after antigen retrieval in EDTA ph 8.0) proved helpful; 
the level of CD68 immunoreactivity directly corresponds 
with the number of macrophages identified by their 
morphological feature.
Prior to the application of the primary antibody, the 
slides for B7-H4 staining were incubated three times 
for 15 minutes in hydrogen peroxide plus absolute 
methanol to block endogenous peroxidase and sub-
mitted to 3% low-fat dried milk diluted 1:100 in PBS to 
perform the non-specific binding. For antigen retrieval, 
the sections were immersed in 10mM sodium citrate 
buffer, pH 6.2. The primary antibody, B7-H4 Antibody, 
rabbit polyclonal (Abbiotec; LLC, San Diego, CA, USA, 
Catalog No. 259473, for research only) was applied 
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in dilution 1:100. The slides were incubated with the 
primary monoclonal antibody in a humidified chamber 
for 1hr at room temperature. 
For RCAS1 immunostaining, the slides were pre-
pared in the same manner as mentioned above and 
submitted to immunohistochemical assay for the mouse 
monoclonal antibody Anti-RCAS1 (Medical and Bio-
logical Laboratories, Naka-ku Nagoya, Japan in DAKO 
Antibody Diluent with Background Reducing Compo-
nents-DAKO, Glostrup, Denmark, dilution 1:1000) in 
the humidified chamber overnight. A semi-quantitative 
interpretation of immunohistochemical results was car-
ried out by two observers, who, working independently 
of each other and having no knowledge of the clinico-
pathological data, reviewed the immunohistochemical 
expression of the B7-H4 antigen, RCAS1 antigen, and 
CD68-positive cells.
An average number of B7-H4- and RCAS1-antigen 
positive macrophages and fibroblasts (identified mor-
phologically) per 1 hpf (high power field) as well as the 
percentage of RCAS1 and B7-H4-antigen immunopos-
itive carcinoma cells were calculated. Macrophages 
and fibroblasts were evaluated in entire slides (at least 
10hpf in each case).
The RCAS1 and B7-H4 expression in the cancer 
cells was graded as follows:
0-lack of any positivity or expression in less than 
1% of the cells; +1-expression 1–10% of the carci-
noma cells; +2-positivity of 2–0% of the carcinoma 
cells; +3-expression in more than 50% of the carci-
noma cells.
Statistical Analysis
The distribution of variables in the study groups of 
the patients checked with the use of the Shapiro-Wilk 
test showed that each of the patients was, in fact, dif-
ferent from normal. The statistical significance between 
the groups was determined by the Kruskal-Wallis test, 
one-way analysis of variance by ranks. The Mann-Whit-
ney U test was then used as applicable. All statistical 
analyses were carried out with the Statistica 8.0 software 
program. A p-value < 0.05 was considered indicative 
of statistical significance. 
Results and Discussion
RCAS1
RCAS1-immunopositive cancer cells were identified 
in 65% of the examined tissue samples of squamous 
cell carcinoma of the palatine tonsils. RCAS1-immu-
nopositive macrophages were found in 40% of exam-
ined tissue samples of the cancer microenvironment. 
Statistically, significantly higher levels of RCAS1 was 
identified in cancer than in the microenvironment 
(p < 0.05) (Table 3). Statistically, significantly higher 
levels of RCAS1 immunoreactivity were detected in the 
cancer microenvironment of patients with the presence 
of lymph node metastases than in patients without such 
metastases (p < 0.05) (Table 4). Statistically significant-
ly higher RCAS1 immunoreactivity levels were found in 
Table 3. The levels of B7H4, RCAS1 and CD68 antigens immunoreactivity in carcinoma and stroma
Antigen Cancer-squamous cell carcinoma  
of the palatine tonsils
Stroma p-value
B7H4 2 (2) 1 (0) < 0.0001
RCAS1 2 (1) 0 (0) < 0.0001
CD68 1 (1) 2(2) < 0.0001
Table 4. The levels of B7H4, RCAS1 and CD68 antigens immunoreactivity in patients with respect to the presence of 
lymph node metastases 
Antigen N0 (n = 24)
Median
(O3-Q1)
N+ (n = 6)
Median
(O3-Q1)
p-value
Tumor
B7H4
2 (1) 2 (2) 0.01
Stroma Macrophages B7H4 0 (1) 1 (1) 0.04
Stroma Fibroblasts B7H4 0 (0) 1 (1) p < 0.001
Tumor
RCAS1
1 (1) 2 (1) p < 0.001
Stroma Macrophages RCAS1 0 (0) 0 (1) 0.01
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the tumour microenvironment of patients with G3 tu-
mours than in those patients with G1 and G2 tumours 
(p < 0.05) (Table 5). Moreover, statistically, significantly 
higher RCAS1 immunoreactivity levels were identified 
in the tumour microenvironment of patients with T3 and 
T4 tumours than in those patients with T1 and T2 tu-
mours (p < 0.05) (Table 6). Furthermore, a statistically 
significantly higher number of RCAS1-immunopositive 
macrophages in the tumour microenvironment were 
detected in patients with the presence of lymph node 
metastases (p < 0.05) (Table 4). 
B7H4
B7-H4-positive cancer cells were identified in all 
the tissue samples of palatine tonsil squamous cell 
carcinoma. Within the cancer microenvironment, B7-
H4 immunopositive macrophages were found in 60% 
of the cases, and B7-H4 immunopositive fibroblasts in 
85% of the cases. Statistically, significantly higher levels 
of B7-H4 immunoreactivity in the tumour were identified 
in patients with the presence of lymph node metastases 
than in those patients without such metastases. No sta-
tistically significant differences were identified between 
B7-H4 immunoreactivity levels and the tumour grade 
and size. A statistically significantly higher number 
of B7-H4-positive cancer-associated fibroblasts and 
macrophages was identified in those patients with 
the presence of lymph node metastases (p < 0.05). 
No statistically significant differences, however, were 
found between the B7-H4 immunoreactivity levels in 
cancer-associated fibroblasts and macrophages and 
the tumour size and grade.
CD68
CD68 immunopositive cells were identified in all the 
cancerous tissue samples and their tumour microen-
vironments. Statistically significantly higher number of 
CD68 positive cells was identified in the stroma than in 
cancer samples. No statistically significant differences 
were identified between the number of CD-68 immu-
nopositive cells and the clinicopathological parameters, 
including tumour size, tumour grade, and lymph node 
status (Table 3).
In the reference group of chronic tonsillitis tissue 
samples, an intensive B7H4 antigen immunoreactivity 
was observed in the epithelium of the palatine crypts 
(Figure 1A), but the surface epithelium of the palatine 
tonsils did not demonstrate B7-H4 antigen immuno-
reactivity (Figure 1B). Single cells within the tonsillar 
lymphatic nodules and intramodular space also demon-
strated B7-H4 antigen immunoreactivity (Figure 2). 
These cells were identified as macrophages. 
Table 5. The levels of B7H4, RCAS1 and CD68 with respect to the tumour grade
Antigen G1 + G2 (n = 20)
Median
(O3-Q1)
G3 (n = 10)
Median
(O3-Q1)
p-value
Tumor
B7H4
2 (2) 2 (2) NS
Microenvironment Macrophages B7H4 0 (1) 0 (1) NS
Microenvironment Fibroblasts B7H4 0 (0) 0 (0) NS
Tumor
RCAS1
1 (1) 2 (1) p < 0.001
Microenvironment Macrophages RCAS1 0 (0) 0 (0) NS
Table 6. The levels of B7H4, RCAS1 and CD68 with respect to the tumour size
Antigen T1 + T2 (n = 21)
Median
(O3-Q1)
T3 + T4 (n = 9)
Median
(O3-Q1)
p-value
Tumor 
B7H4
2 (2) 2 (2) NS
Microenvironment Macrophages B7H4 0 (1) 0 (1) NS
Microenvironment Fibroblasts B7H4 0 (0) 0 (0) NS
Tumor 
RCAS1
1 (1) 2 (2) p < 0.001
Microenvironment Macrophages RCAS1 0 (0) 0 (0) NS
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Figure 2. Scattered cells (macrophages) with B7H4 antigen immunoreactivity in tonsillar nodules and in intramodular 
space (stars). Magnification A-20x, B-40x
Figure 1. An intensive B7H4 antigen immunoreactivity in the epithelium of tonsillar crypts in chronic tonsillitis (arrows) 
and no B7H4 antigen immunoreactivity in the surface epithelium (stars) of the palatine tonsil. Magnification A-40x, B-20x
A B
A B
In the present study, we have shown that the B7-
H4 antigen was over-expressed in cancerous tonsillar 
tissue and was significantly higher in those patients 
with the presence of lymph node metastases. The 
immunoreactivity of B7-H4 in the cancerous tumour 
microenvironment was represented by macrophages 
and cancer-associated fibroblasts and was statistically 
significantly associated with the presence of lymph 
node metastases. The results presented remain in 
agreement with the study concerning oral squamous 
cell carcinoma, where B7-H4 antigen expression was 
significantly associated with pathological grade and 
lymph node status. Moreover, it was demonstrated 
that patients with high B7-H4 expression had poorer 
overall survival compared with those with low B7-
H4 expression, and it was suggested that B7-H4 could 
be a potential target in the treatment of oral squamous 
cell carcinoma [12]. All these findings suggest that 
B7-H4 antigen immunoreactivity by tonsillar cancer 
cells and microenvironment macrophages, together 
with cancer-associated fibroblasts, are related to the 
potential to develop metastases. In a meta-analysis, 
it was demonstrated that elevated B7-H4 is an inde-
pendent predictor of poorer overall survival in patients 
with solid tumours [21]. In ovarian cancer, Kryczek 
et al. have determined that ovarian cancer cells and 
tumour-associated macrophages express B7-H4 and 
inhibit TAA-specific T-cell proliferation, cytokine pro-
duction, and cytotoxicity [7]. The intensity of the B7-
H4 expression of the macrophages was associated with 
tumour-infiltrating Treg cells and negatively predicted 
patient survival.
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The studies on B7-H4 antigen over-expression in 
cancer cells and in the tumour microenvironment sug-
gest that B7-H4 over-expression reflects the growing 
resistance to the immune response by various mecha-
nisms. It has been shown that B7-H4 plays an important 
role in inhibiting CD4-positive and CD8-positive cell 
proliferation [22]. Chen et al. have demonstrated that 
B7-H4 participates in inducing cytotoxic lymphocyte 
apoptosis in patients with Lewis lung carcinoma [8]. 
B7-H4 stimulation was observed to induce cell cycle 
arrest in different phases and inhibited T-cells [22]. 
B7-H4 inhibited cytokine production and cytotoxicity of 
T cells [22]. Cancer-associated B7-H4 was resistant to 
T-cell mediated cytotoxic activity [23]. Various studies 
have recently demonstrated that the blockade of can-
cer-associated B7-H4 may enhance T-cell-mediated 
antitumor immunity, and this knowledge could lead to 
the formulation of a new therapeutic strategy for cancer 
treatment [9, 24–25, 26–29].
In the present study, B7-H4 antigen immunoreac-
tivity was also observed in the palatine tonsils taken 
from patients with chronic tonsillitis. Immunoreactivity 
was detected in the epithelium of tonsillar crypts and 
in the macrophages of lymph nodules as well as in 
intramodular spaces. The results confirmed that B7-
H4 has an important immunoregulatory role and that 
the region of stratified crypt epithelium, along with the 
lymph nodules and intramodular space in the palatine 
tonsils, is responsible for direct contact with antigens 
and the regulation of the immune response.
In the present study, RCAS1 antigen over-expres-
sion was identified in palatine tonsil squamous cell car-
cinoma cells and associated with the presence of lymph 
node metastases. RCAS1 is a poor prognostic factor in 
cases involving 15 different types of cancers [17]. In the 
present study, the number of RCAS1-immunopositive 
macrophages in the cancer microenvironment was sig-
nificantly associated with the presence of lymph node 
metastases. Similarly, Sonoda et al. have observed that 
RCAS1 expression in the tumour microenvironment 
correlates with the potential to develop metastases. In 
our earlier reports on head and neck (pharyngeal and 
laryngeal) cancer, RCAS1 over-expression in both 
a tumour and in the tumour microenvironment was also 
associated with the potential to develop metastases, 
confirming that RCAS1 is an indicator of poor prognosis 
in these tumors [2, 17, 20].
Conclusion
Our study seems to indicate that both RCAS1- and 
B7-H4- immunopositive macrophages, together with 
B7H4 immunopositive cancer-associated fibroblasts, 
may play an important role in creating the suppressive 
profile of the tumour microenvironment of patients with 
tonsillar cancer. Furthermore, it also seems to show that 
the over-expression of B7-H4 in the microenvironment 
plays a significant role in promoting tumour progres-
sion and metastases. We have thus concluded that 
B7H4 may be an important factor in immune evasion in 
patients with tonsillar cancer. It would also seem to con-
stitute a new target for immunotherapy in such patients.
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